Lactose Intolerance Treatment Market Report 2026

The lactose intolerance treatment market size has grown strongly in recent years. It will grow from $34.43 billion in 2025 to $36.96 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising lactose intolerance prevalence, limited availability of lactose-free products, low consumer awareness, reliance on traditional remedies, increasing gastrointestinal disorders.

The lactose intolerance treatment market size is expected to see strong growth in the next few years. It will grow to $49.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growing demand for personalized therapies, technological advancements in enzyme formulations, expansion of functional dairy alternatives, increased healthcare expenditure, rising homecare adoption. Major trends in the forecast period include personalized lactose intolerance therapies, growth of functional foods and dairy alternatives, increased adoption of enzyme supplements, awareness and education on digestive health, expansion of home-based treatment solutions.

The lactose intolerance treatment market is expected to benefit from the growing global population during the forecast period. The expansion of the global population and shifting dietary patterns have contributed to an increase in the number of individuals with lactose intolerance, driving the demand for effective treatments and management solutions. This demographic change, along with rising awareness of lactose intolerance, is likely to spur innovation and investment in therapeutic options. For example, in January 2024, the United States Census Bureau, a U.S.-based government agency, projected that the global population would reach 8,019,876,189, reflecting an increase of 75,162,541 (0.95%) from 2023. As a result, the growing population is expected to drive the demand for the lactose intolerance treatment market.

Major companies in the lactose intolerance treatment market are focusing on developing innovative solutions, such as advanced sugar-reduction and lactose-modification technologies, to meet the growing demand for low-lactose, low-sugar, and digestion-friendly dairy products. These technologies work by enzymatically breaking down lactose and reducing natural sugar content, offering a functional alternative to traditional lactose-free processing methods while enhancing the nutritional profiles of products. For example, in July 2023, Nestlé, a Switzerland-based food and beverage company, introduced a versatile, cost-effective sugar-reduction technology that can be applied across multiple product categories. This technology not only reduces total sugars but also allows for the creation of low-lactose and skimmed milk-based products, addressing both lactose intolerance and sugar-reduction needs for consumers.

In December 2023, Kerry Group plc, an Ireland-based taste and nutrition company, acquired part of the global lactase enzyme business of Chr. Hansen Holding A/S and Novozymes A/S for an undisclosed amount. This acquisition aligns with Kerry's strategic focus on expanding its biotechnology solutions and facilitating the production of lactose-free and sugar-reduced dairy products, meeting the growing consumer demand driven by lactose intolerance. Novozymes A/S, a Denmark-based biotechnology company, specializes in developing industrial enzymes and microbial solutions for applications across sectors like agriculture, food, bioenergy, and household care.

Major companies operating in the lactose intolerance treatment market are Abbott Laboratories Inc., Macleods Pharmaceuticals Limited, Ganeden Inc., Deerland Probiotics & Enzymes Inc., Novozymes A/S, Cargill Incorporated, Lupin Pharmaceuticals Inc., Nestlé S.A., Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Wockhardt Ltd., Alkem Laboratories Limited, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., DuPont Nutrition & Biosciences Inc., Kerry Group plc, Koninklijke DSM N.V., Solvay S.A., Chr. Hansen Holding A/S, Bio-Cat Inc.

North America was the largest region in the lactose intolerance treatment market in 2025. The regions covered in the lactose intolerance treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lactose intolerance treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the lactose intolerance treatment market by increasing the cost of imported lactase supplements, probiotics, and specialized dairy products, disrupting supply chains in regions like North America and Europe. Segments such as enzyme lactase supplements and probiotic formulations are most impacted, while regions relying heavily on imports face price pressures. However, tariffs have also incentivized local manufacturing and sourcing, promoting domestic production of lactose-free foods and supplements, which can enhance product availability and reduce dependency on imports.

The lactose intolerance treatment market research report is one of a series of new reports that provides lactose intolerance treatment market statistics, including lactose intolerance treatment industry global market size, regional shares, competitors with a lactose intolerance treatment market share, detailed lactose intolerance treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lactose intolerance treatment industry. This lactose intolerance treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lactose intolerance treatment addresses a condition that affects the digestive system, caused by the insufficient production of lactase, an enzyme necessary for digesting lactose. This condition can lead to symptoms such as abdominal pain, flatulence, bloating, cramps, acidity, and diarrhea. The treatment typically involves substituting the natural lactase enzyme that the body fails to produce.

The treatments for lactose intolerance include food supplements, enzyme lactase supplements, probiotics, and other approaches. Food supplements are designed to compensate for nutritional deficiencies, ensure adequate intake of specific nutrients, or support particular physiological functions. The types of lactose intolerance include primary, secondary, congenital, and developmental lactose intolerance. These treatments are administered through oral and injectable methods and are used in settings such as hospitals, homecare, specialty clinics, and other healthcare environments.

The lactose intolerance treatment market consists of sales of lactase enzyme products, tablets and drops that contain lactase. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.